RPD is at the centre of a post-earnings squeeze this week, with the stock up 24% in five sessions even as short sellers add to already-elevated positions and analysts lift targets without raising conviction.
Earnings drove everything. Rapid7 reported Q2 after the close on August 10, and the stock responded with a 15.6% single-day gain — the company's strongest post-print reaction in recent history. A similar-sized move followed the prior quarter's August 6 release. The pattern is becoming consistent: large misreads on the downside, followed by sharp reversals. The stock closed Tuesday at $13.38, roughly double where insiders were selling just three months ago.
What makes this week's setup genuinely interesting is the contrast between price action and short positioning. Shorts are not covering — they are rebuilding. Short interest climbed 4.6% across the week to 12.0% of the free float, hitting 7.85 million shares as of August 11. That follows a more modest drift higher over the prior month. With the stock up 24% on the week, shorts adding into a post-earnings rally is a deliberate decision, not inertia. The lending market offers them no friction: availability is deep at 1,274%, meaning there are roughly thirteen shares available to borrow for every one currently lent out. Cost to borrow is negligible at 0.36%, down sharply from mid-July levels above 0.65%. There is no squeeze pressure from the supply side.
Options traders have moved the other direction. The put/call ratio has eased to 0.91, around 1.3 standard deviations below its 20-day average of 0.94 — a shift toward calls relative to the defensive posture that had characterised the stock through most of July and late June. The 52-week low on the PCR is 0.10, so this is not an extreme, but the directional move matches the post-earnings sentiment reset: less hedging demand than a week ago.
The analyst response to the print was unanimous in one narrow way: every firm on the Street raised their price target. But none upgraded their rating. JP Morgan moved to $12 from $7. Barclays went to $12 from $6.50. UBS matched at $12. Stifel and Scotiabank both lifted to $13 and $10.15 respectively. Susquehanna was the most aggressive, raising to $15, but kept a Neutral. The mean target now sits at $11.71 — already below Tuesday's close of $13.38. That disconnect is worth noting: the Street nearly doubled its targets overnight and still couldn't get ahead of the tape. The bull case centres on MDR and AI-SOC optionality, a leadership transition bringing operational discipline, and a potential recovery from negative ARR growth. The bear case is equally direct: intense competition, a history of missed expectations, and no hard evidence in guidance that the newer growth vectors are inflecting. DA Davidson maintained an Underperform at $9 — the one dissonant voice in an otherwise flat chorus. On valuation, the EV/EBITDA has compressed modestly over the past 30 days, and the P/E of 6.9x reflects a market that had been pricing in ongoing distress rather than recovery.
Institutional data adds a notable footnote. BlackRock reported adding 2.4 million shares as of July 31, taking its stake to 13.4% of the company. Jana Partners, the activist manager, holds a 10% position unchanged since March. Those two alone account for nearly a quarter of shares outstanding. Jana's continued presence is a live variable: activist campaigns in beaten-down software names often play out over 12–18 month horizons, and Rapid7's leadership transition — long-time CEO Corey Thomas stepping back to Executive Chairman, Wael Mohamed taking the top role — fits the pattern of board-driven operational reset that activists typically push for. Insider activity, by contrast, has been entirely on the sell side, with small-dollar transactions from the Chief Accounting Officer and Mohamed himself in June. Values were trivial and largely look like scheduled sales, but no insider has bought into the lows.
The ORTEX short score has nudged above 50 for the first time in the recent window, closing August 11 at 51.9 — a mid-table reading that suggests no strong directional lean from the composite signal. What to watch next is whether short sellers continue rebuilding above $13, the level where analysts are clustering their targets, or whether the weight of a 12% short interest starts to matter if any further positive datapoint on ARR trajectory emerges ahead of the next reporting cycle. Peer QLYS gained 16.9% on the week and SPT added 13.2%, so RPD's move was large but not anomalous in the context of a broader software rally — the question is whether the company-specific story now justifies a premium to that group rather than a discount.
See the live data behind this article on ORTEX.
Open RPD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
